175 related articles for article (PubMed ID: 7833279)
1. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.
Hellström-Lindberg E
Br J Haematol; 1995 Jan; 89(1):67-71. PubMed ID: 7833279
[TBL] [Abstract][Full Text] [Related]
2. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Hellström-Lindberg E; Gulbrandsen N; Lindberg G; Ahlgren T; Dahl IM; Dybedal I; Grimfors G; Hesse-Sundin E; Hjorth M; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Oberg G; Porwit-MacDonald A; Rådlund A; Samuelsson J; Tangen JM; Winquist I; Wisloff F;
Br J Haematol; 2003 Mar; 120(6):1037-46. PubMed ID: 12648074
[TBL] [Abstract][Full Text] [Related]
3. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
[TBL] [Abstract][Full Text] [Related]
4. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
[TBL] [Abstract][Full Text] [Related]
5. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
[TBL] [Abstract][Full Text] [Related]
6. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.
Yoshida Y; Anzai N; Kawabata H; Kohsaka Y; Okuma M
Ann Hematol; 1993 Apr; 66(4):175-80. PubMed ID: 8485205
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.
Mohr B; Herrmann R; Huhn D
Acta Haematol; 1993; 90(2):65-70. PubMed ID: 8285020
[TBL] [Abstract][Full Text] [Related]
8. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
Stenke L; Wallvik J; Celsing F; Hast R
Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
[TBL] [Abstract][Full Text] [Related]
9. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes.
Bernell P; Stenke L; Wallvik J; Hippe E; Hast R
Leuk Res; 1996 Aug; 20(8):693-9. PubMed ID: 8913323
[TBL] [Abstract][Full Text] [Related]
10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
11. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes.
; Ferrini PR; Grossi A; Vannucchi AM; Barosi G; Guarnone R; Piva N; Musto P; Balleari E
Br J Haematol; 1998 Dec; 103(4):1070-4. PubMed ID: 9886322
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone?
Musto P; Falcone A; Carotenuto M; Catalano L; Cennamo A; Rotoli B
Blood; 1994 Sep; 84(5):1687-8. PubMed ID: 7520783
[No Abstract] [Full Text] [Related]
15. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients.
Terpos E; Mougiou A; Kouraklis A; Chatzivassili A; Michalis E; Giannakoulas N; Manioudaki E; Lazaridou A; Bakaloudi V; Protopappa M; Liapi D; Grouzi E; Parharidou A; Symeonidis A; Kokkini G; Laoutaris NP; Vaipoulos G; Anagnostopoulos NI; Christakis JI; Meletis J; Bourantas KL; Zoumbos NC; Yataganas X; Viniou NA;
Br J Haematol; 2002 Jul; 118(1):174-80. PubMed ID: 12100145
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes--response patterns.
Lewinski UH; Floru S; Cohen AM; Mittelmann M
Leuk Lymphoma; 1994 Sep; 15(1-2):149-52. PubMed ID: 7858493
[TBL] [Abstract][Full Text] [Related]
17. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.
Negrin RS; Stein R; Doherty K; Cornwell J; Vardiman J; Krantz S; Greenberg PL
Blood; 1996 May; 87(10):4076-81. PubMed ID: 8639764
[TBL] [Abstract][Full Text] [Related]
18. Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters.
Bowen DT; Culligan D; Beguin Y; Kendall R; Willis N
Leukemia; 1994 Jan; 8(1):151-5. PubMed ID: 8289479
[TBL] [Abstract][Full Text] [Related]
19. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
Hellström-Lindberg E; Negrin R; Stein R; Krantz S; Lindberg G; Vardiman J; Ost A; Greenberg P
Br J Haematol; 1997 Nov; 99(2):344-51. PubMed ID: 9375752
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes.
Isnard F; Najman A; Jaar B; Fenaux P; Baillou C; Khoury E; Labopin M; Laporte JP; Woler M; Gorin NC
Leuk Lymphoma; 1994 Jan; 12(3-4):307-14. PubMed ID: 8167562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
